Clinical Trial Update: Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of MDV3100 (enzalutamide) in combination with docetaxel in men with advanced prostate cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• MDV3100 (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-04-22